Logo image of NSPR

INSPIREMD INC (NSPR) Stock Fundamental Analysis

NASDAQ:NSPR - Nasdaq - US45779A8466 - Common Stock - Currency: USD

3.19  +0.09 (+2.9%)

After market: 3.17 -0.02 (-0.63%)

Fundamental Rating

4

Overall NSPR gets a fundamental rating of 4 out of 10. We evaluated NSPR against 189 industry peers in the Health Care Equipment & Supplies industry. No worries on liquidiy or solvency for NSPR as it has an excellent financial health rating, but there are worries on the profitability. NSPR is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

NSPR had negative earnings in the past year.
NSPR had a negative operating cash flow in the past year.
In the past 5 years NSPR always reported negative net income.
In the past 5 years NSPR always reported negative operating cash flow.
NSPR Yearly Net Income VS EBIT VS OCF VS FCFNSPR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5M -10M -15M -20M

1.2 Ratios

With a Return On Assets value of -55.93%, NSPR is not doing good in the industry: 71.12% of the companies in the same industry are doing better.
NSPR has a Return On Equity (-68.28%) which is in line with its industry peers.
Industry RankSector Rank
ROA -55.93%
ROE -68.28%
ROIC N/A
ROA(3y)-51.46%
ROA(5y)-63.06%
ROE(3y)-67.08%
ROE(5y)-94.91%
ROIC(3y)N/A
ROIC(5y)N/A
NSPR Yearly ROA, ROE, ROICNSPR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200 -200 400 -400 600 800

1.3 Margins

NSPR has a Gross Margin of 22.61%. This is amonst the worse of the industry: NSPR underperforms 80.21% of its industry peers.
In the last couple of years the Gross Margin of NSPR has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for NSPR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 22.61%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y108.5%
GM growth 5Y0.95%
NSPR Yearly Profit, Operating, Gross MarginsNSPR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400 -600

More info and screens

7

2. Health

2.1 Basic Checks

NSPR does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NSPR has been increased compared to 1 year ago.
The number of shares outstanding for NSPR has been increased compared to 5 years ago.
There is no outstanding debt for NSPR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NSPR Yearly Shares OutstandingNSPR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M
NSPR Yearly Total Debt VS Total AssetsNSPR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -2.20, we must say that NSPR is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -2.20, NSPR is not doing good in the industry: 62.03% of the companies in the same industry are doing better.
There is no outstanding debt for NSPR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.2
ROIC/WACCN/A
WACC9.11%
NSPR Yearly LT Debt VS Equity VS FCFNSPR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M 20M 30M

2.3 Liquidity

A Current Ratio of 6.39 indicates that NSPR has no problem at all paying its short term obligations.
NSPR has a better Current ratio (6.39) than 85.03% of its industry peers.
NSPR has a Quick Ratio of 6.05. This indicates that NSPR is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 6.05, NSPR belongs to the best of the industry, outperforming 87.17% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.39
Quick Ratio 6.05
NSPR Yearly Current Assets VS Current LiabilitesNSPR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 50.66% over the past year.
NSPR shows a strong growth in Revenue. In the last year, the Revenue has grown by 24.56%.
NSPR shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.50% yearly.
EPS 1Y (TTM)50.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-6.67%
Revenue 1Y (TTM)24.56%
Revenue growth 3Y35.58%
Revenue growth 5Y11.5%
Sales Q2Q%16.32%

3.2 Future

Based on estimates for the next years, NSPR will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.35% on average per year.
NSPR is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 67.86% yearly.
EPS Next Y26.33%
EPS Next 2Y-14.16%
EPS Next 3Y-5.55%
EPS Next 5Y13.35%
Revenue Next Year13.11%
Revenue Next 2Y30.1%
Revenue Next 3Y63.78%
Revenue Next 5Y67.86%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
NSPR Yearly Revenue VS EstimatesNSPR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 10M 20M 30M 40M
NSPR Yearly EPS VS EstimatesNSPR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -1M -2M -3M -4M -5M

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NSPR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year NSPR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NSPR Price Earnings VS Forward Price EarningsNSPR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NSPR Per share dataNSPR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 1.5

4.3 Compensation for Growth

NSPR's earnings are expected to decrease with -5.55% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-14.16%
EPS Next 3Y-5.55%

More info and screens

0

5. Dividend

5.1 Amount

NSPR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INSPIREMD INC

NASDAQ:NSPR (2/21/2025, 8:00:01 PM)

After market: 3.17 -0.02 (-0.63%)

3.19

+0.09 (+2.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-12 2024-11-12/bmo
Earnings (Next)03-11 2025-03-11/amc
Inst Owners40.55%
Inst Owner Change-99.55%
Ins Owners20.74%
Ins Owner Change11.72%
Market Cap83.20M
Analysts82.5
Price Target4.85 (52.04%)
Short Float %0.95%
Short Ratio5.38
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)4.02%
Min EPS beat(2)-13.52%
Max EPS beat(2)21.57%
EPS beat(4)2
Avg EPS beat(4)-2.41%
Min EPS beat(4)-37.25%
Max EPS beat(4)21.57%
EPS beat(8)6
Avg EPS beat(8)8.83%
EPS beat(12)10
Avg EPS beat(12)14.75%
EPS beat(16)13
Avg EPS beat(16)14.67%
Revenue beat(2)1
Avg Revenue beat(2)-0.03%
Min Revenue beat(2)-2.03%
Max Revenue beat(2)1.97%
Revenue beat(4)3
Avg Revenue beat(4)3.29%
Min Revenue beat(4)-2.03%
Max Revenue beat(4)7.01%
Revenue beat(8)7
Avg Revenue beat(8)5.37%
Revenue beat(12)10
Avg Revenue beat(12)4.57%
Revenue beat(16)11
Avg Revenue beat(16)-2.55%
PT rev (1m)0%
PT rev (3m)5.56%
EPS NQ rev (1m)2.5%
EPS NQ rev (3m)2.5%
EPS NY rev (1m)0%
EPS NY rev (3m)4.88%
Revenue NQ rev (1m)-0.91%
Revenue NQ rev (3m)-0.91%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.96%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 12.2
P/FCF N/A
P/OCF N/A
P/B 2.01
P/tB 2.01
EV/EBITDA N/A
EPS(TTM)-0.75
EYN/A
EPS(NY)-1.41
Fwd EYN/A
FCF(TTM)-0.79
FCFYN/A
OCF(TTM)-0.74
OCFYN/A
SpS0.26
BVpS1.59
TBVpS1.59
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -55.93%
ROE -68.28%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 22.61%
FCFM N/A
ROA(3y)-51.46%
ROA(5y)-63.06%
ROE(3y)-67.08%
ROE(5y)-94.91%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y108.5%
GM growth 5Y0.95%
F-Score3
Asset Turnover0.14
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 490.98%
Cap/Sales 19.15%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.39
Quick Ratio 6.05
Altman-Z -2.2
F-Score3
WACC9.11%
ROIC/WACCN/A
Cap/Depr(3y)208.03%
Cap/Depr(5y)171.82%
Cap/Sales(3y)7.6%
Cap/Sales(5y)6.79%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-6.67%
EPS Next Y26.33%
EPS Next 2Y-14.16%
EPS Next 3Y-5.55%
EPS Next 5Y13.35%
Revenue 1Y (TTM)24.56%
Revenue growth 3Y35.58%
Revenue growth 5Y11.5%
Sales Q2Q%16.32%
Revenue Next Year13.11%
Revenue Next 2Y30.1%
Revenue Next 3Y63.78%
Revenue Next 5Y67.86%
EBIT growth 1Y-47.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-15.17%
EBIT Next 3Y-18.96%
EBIT Next 5Y-7.65%
FCF growth 1Y-30.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-26.52%
OCF growth 3YN/A
OCF growth 5YN/A